A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
Congenital Bleeding DisorderHaemophilia BThis trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia...
Congenital Bleeding DisorderHaemophilia BThis trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.
Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
Coronary Heart DiseaseCoagulation DisorderIn this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of Anfibatide, a specific glycoprotein Ib antagonist. This study represents the first clinical evidence that Anfibatide exhibits strong anti-platelet effects, excellent reversibility, and low bleeding potential in healthy human subjects.
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
Acquired Bleeding DisorderTraumaThis trial is conducted in Europe. The aim of this trial is to evaluate the efficacy of activated recombinant human factor VIIgiven in conjunction with standard therapy in patients undergoing major orthopaedic surgery following traumatic pelvic or pelvic and acetabular fractures.
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors...
Congenital Bleeding DisorderHaemophilia A With Inhibitors1 moreThis trial is conducted in North America. The aim of this trial is to compare the safety and efficacy of activated recombinant human factor VII in patients with haemophilia A or B undergoing major surgical procedures.
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated...
Congenital Bleeding DisorderHaemophilia AThis trial is conducted in Asia, Europe and North America. The purpose of the trial is to evaluate the safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia A.
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma...
Acquired Bleeding DisorderIntracerebral HaemorrhageThis trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth in acute Intracerebral Hemorrhage (ICH).
Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic...
Acquired Bleeding DisorderBleeding During/Following SurgeryThis trial is conducted in Europe, North America and Oceania. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in subjects undergoing orthotopic liver transplantation surgery.
Factor VIIa in Acute Intracerebral Haemorrhage
Acquired Bleeding DisorderIntracerebral HaemorrhageThis trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.
Use of NovoSeven® in Active Variceal Bleeding
Acquired Bleeding DisorderCirrhosisThis trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.
